Scarica l'app Stockscreener
31.10
3.69%
-1.19
Dopo l'orario di chiusura:
31.10
Precedente Chiudi:
$32.29
Aprire:
$31.88
Volume 24 ore:
646.94K
Relative Volume:
0.78
Capitalizzazione di mercato:
$2.03B
Reddito:
$10.00M
Utile/perdita netta:
$-425.15M
Rapporto P/E:
-3.4189
EPS:
-9.0964
Flusso di cassa netto:
$-210.48M
1 W Prestazione:
-5.53%
1M Prestazione:
-2.78%
6M Prestazione:
+19.98%
1 anno Prestazione:
+57.15%
Intervallo 1D:
$30.73
$31.89
Intervallo di 1 settimana:
$30.73
$33.84
Portata 52W:
$13.50
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Nome
Zenas Biopharma Inc
Settore
Industria
Telefono
857-271-2954
Indirizzo
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
31.10 | 2.10B | 10.00M | -425.15M | -210.48M | -9.0964 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-20 | Iniziato | Wedbush | Outperform |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-05 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-08 | Iniziato | Citigroup | Buy |
| 2024-10-08 | Iniziato | Guggenheim | Buy |
| 2024-10-08 | Iniziato | Jefferies | Buy |
| 2024-10-08 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Zenas Biopharma Inc Borsa (ZBIO) Ultime notizie
Wellington Management Group LLP Adds 4,972,315 Shares of Zenas B - GuruFocus
ZBIO: Obexelimab nears FDA review with strong market potential and pivotal data readouts ahead - TradingView
Zenas BioPharma at Citi summit: pipeline bets and cash runway By Investing.com - Investing.com India
A 10% slice of Zenas BioPharma (NASDAQ: ZBIO) sits with one investment group - Stock Titan
Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event - GlobeNewswire
InnoCare reports 10.4% passive Zenas BioPharma stake | ZBIO SEC FilingForm SCHEDULE 13G/A - Stock Titan
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences - Yahoo Finance
Director at Zenas BioPharma (ZBIO) granted 37,000 options - Stock Titan
Enavate Sciences GP, LLC Reduces Zenas BioPharma Inc (ZBIO) Stak - GuruFocus
Zenas (ZBIO) Levels: Advances 2.12% to $32.29 in the Latest Reading; Levels: the Price Remains Bounded by the Supplied Support and Resistance at the CloseGap and Go - siam.in
Zenas BioPharma (ZBIO) Is Up 9.4% After Wider Losses And Board AdditionHas The Bull Case Changed? - simplywall.st
Zenas BioPharma (ZBIO) holder sells 673,755 shares in open-market trade - Stock Titan
Zenas BioPharma (ZBIO) affiliate plans August 2026 share sale - Stock Titan
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Zenas BioPharma hires receive stock awards vesting through 2030 - Stock Titan
HC Wainwright Predicts Higher Earnings for Zenas BioPharma - MarketBeat
SR One's stake in Zenas BioPharma (ZBIO) drops over 1 point without selling - Stock Titan
Morgan Stanley Maintains Zenas BioPharma(ZBIO.US) With Hold Rating, Raises Target Price to $32 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
ZBIO Q1 2026 Earnings: Narrower-than-Expected Loss Signals Cost Discipline for Clinical-Stage BiotechDividend Growth Analysis - vinanet.vn
Walleye Capital LLC Takes $5.31 Million Position in Zenas BioPharma, Inc. $ZBIO - MarketBeat
Zenas BioPharma's (ZBIO) Buy Rating Reaffirmed at Guggenheim - MarketBeat
Zenas BioPharma's (ZBIO) Outperform Rating Reiterated at Wedbush - MarketBeat
Zenas BioPharma (ZBIO) Is Down 9.2% After Wider Losses And Leadership ChangesWhat's Changed - simplywall.st
ZBIO SWOT Analysis: Financial Challenges and Strategic Opportuni - GuruFocus
Zenas BioPharma (NASDAQ:ZBIO) Issues Earnings Results - MarketBeat
Zenas BioPharma Releases Q2 2026 Financial Results - AlphaStreet
Zenas BioPharma, Inc. Announces Chief Financial Officer Changes, Effective September 30, 2026 - marketscreener.com
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.6% on Disappointing Earnings - MarketBeat
Zenas BioPharma Q2 Results: EPS Misses, Sales Fall 95% - scanx.trade
Zenas BioPharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Zenas Biopharma Inc For: 13 August By Investing.com - Investing.com Canada
Zenas BioPharma's Q2 Net Loss Widens; CFO to Step Down - marketscreener.com
Earnings Flash (ZBIO) Zenas BioPharma Posts Q2 Loss $1.77 a Share, vs. FactSet Est of $1.12 Loss - marketscreener.com
Zenas BioPharma, Inc. 2026: Revenue $1M, Net income ($111.46M), EPS ($1.77) — 10-Q Summary - TradingView
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Earnings Flash (ZBIO) Zenas BioPharma, Inc. Reports Q2 Revenue $1.0M - marketscreener.com
Zenas BioPharma Reports $111.5 Million Second-Quarter Net Loss - Quiver Quantitative
Zenas BioPharma (ZBIO) Slides 3.55% to $31.29 as Biotech Sentiment Turns CautiousTotal Put Call - dars.gov.et
Zenas BioPharma (ZBIO) Edges Higher to $32.44 as Biotech Momentum BuildsMA Cross Alert - Vinanet
Zenas BioPharma (ZBIO) Rises 1.41% to $32.44 as Shares Hold Above Key SupportSynthetic Long - vinanet.vn
Zenas BioPharma (ZBIO) Holds Gains Above $32 as Bullish Momentum BuildsIndex Put Call - dars.gov.et
ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, In - The National Law Review
Zenas BioPharma, Inc. (ZBIO): Investor Outlook On A Potential 35% Upside - DirectorsTalk Interviews
Zenas BioPharma (ZBIO) Holds Firm at $32.43 as Biotech Sentiment SteadiesBreakout Trade - vinanet.vn
Zenas BioPharma (ZBIO) Edges Up 0.97% as Shares Hold Between Support and ResistanceCash Flow Strong Stocks - vinanet.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, In - The National Law Review
Zenas BioPharma (ZBIO) Projected to Release Quarterly Earnings on Tuesday - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Levi & Korsinsky Urges Zenas BioPharma, Inc. (ZBIO) Shareholders to Act Before Lead Plaintiff Deadline June 16, 2025 - The National Law Review
Zenas Biopharma Inc (ZBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Zenas Biopharma Inc Azioni (ZBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):